Talha Badar and Francesca Palandri/LinkedIn
Jun 12, 2026, 16:13
Talha Badar: Excellent Talk by Francesca Palandri on ET and PV at EHA 2026
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, shared a post on X:
“Excellent talk by Dr. Francesca Palandri on ET and PV at EHA 2026
Key takeaways:
Hydroxyurea remains the main 1st-line cytoreductive therapy, but care is increasingly individualized.
Emerging directions:
- Hepcidin modulation in PV, rusfertide and TMPRSS6 inhibitors
- CALR-targeted therapy, mAb and bispecific T-cell engagers
- Multidisciplinary care, including CV risk, fertility, dermatology, thrombosis, QoL
The future of MPN care is moving beyond count control toward disease biology, iron regulation, immune targeting, and patient-centered care.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026